New drug for bone loss called Skelid (SKEL-id, tiludronate)

April 1997

   Sanofi is launching a new drug for bone loss called Skelid (SKEL-id, tiludronate). It's a bisphosphonate...similar to Fosamax and Didronel (etidronate).

   Skelid is initially approved for Paget's disease. A three-month course works as well as six months of etidronate.

   But the real interest is in determining if Skelid is useful for osteoporosis...like Fosamax. We'll keep you posted.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote